Comparative analysis of phase III migrating motor complexes in stomach and small bowel using wireless motility capsule and antroduodenal manometry

2012 ◽  
Vol 24 (4) ◽  
pp. 332-e165 ◽  
Author(s):  
R. Brun ◽  
W. Michalek ◽  
B. C. Surjanhata ◽  
H. P. Parkman ◽  
J. R. Semler ◽  
...  
Keyword(s):  
Comparative Analysis ◽  
Small Bowel ◽  
Phase Iii ◽  
Wireless Motility Capsule ◽  
Antroduodenal Manometry

scholarly journals Gastrointestinal Physiology Before and After Duodenal Switch with Comparisons to Unoperated Lean Controls: Novel Use of the SmartPill Wireless Motility Capsule

2021 ◽  
Author(s):  
Khalid Elias ◽  
Per M. Hellström ◽  
Dominic-Luc Webb ◽  
Magnus Sundbom
Keyword(s):  
Small Bowel ◽  
Transit Time ◽  
Duodenal Switch ◽  
Rating Scale ◽  
Gastrointestinal Symptoms ◽  
Small Bowel Transit ◽  
Gastrointestinal Physiology ◽  
Time Points ◽  
Small Bowel Transit Time ◽  
Wireless Motility Capsule

Abstract Purpose Bariatric surgery alters gastrointestinal anatomy. In this exploratory study, the SmartPill® wireless motility capsule (WMC) was used to study changes in gastrointestinal physiology following biliopancreatic diversion with duodenal switch (BPD/DS). Material and Methods Twenty-eight BPD/DS patients (35 ± 11 years, 50% females, body mass index [BMI] 56 ± 5) were to be examined preoperatively and postoperatively. In addition to transit time, appetite control and gastrointestinal symptoms were studied by patient-scored questionnaires (visual analogue scale and Gastrointestinal Symptom Rating Scale (GSRS)). Data was compared to 41 lean unoperated controls. Results About 1.8 years postoperatively, 18 patients (BMI 35.8 ± 8.3) returned for a second WMC test. As expected, small bowel transit time was reduced, from 3.9 ± 1.6 h to 2.8 ± 2.0, p = 0.02, and at both these time points, it was shorter than in lean controls (5.4 ± 1.9 h, p = 0.001). Postoperatively, a trend towards reduced colon and whole gut transit times was seen in BPD/DS-patients, thus approaching those of lean controls. Surprisingly, BPD/DS patients scored higher satiety than controls preoperatively as well as increased hunger and desire to eat postoperatively. Compared to lean, BPD/DS patients reported a higher total GSRS score at both time points (1.2 ± 0.2 vs 1.7 ± 0.6 and 2.3 ± 0.5, p < 0.001). Postoperatively, the scores for diarrhea and indigestion increased. Conclusions The novel use of the SmartPill system in BPD/DS patients gave the expected readouts. Although small bowel transit time was further shortened after BPD/DS, whole gut transit time did not differ from controls. Typical gastrointestinal symptoms were reported postoperatively. Graphical abstract

Small intestinal motility in fasted and postprandial states: effect of transient vagosympathetic blockade

1987 ◽  
Vol 252 (3) ◽  
pp. G301-G308 ◽  
Author(s):  
S. A. Chung ◽  
N. E. Diamant
Keyword(s):  
Small Bowel ◽  
Intestinal Motility ◽  
Gastric Fundus ◽  
Phase Iii ◽  
Entire Small Bowel ◽  
Vagal Blockade ◽  
Small Intestinal Motility ◽  
Proximal Small Bowel ◽  
Small Intestinal ◽  
Gastric Contractions

We investigated vagal control of the migrating myoelectric complex (MMC) and postprandial pattern of the canine small intestine. Gastric and small intestinal motility were monitored in six conscious dogs. The vagosympathetic nerves, previously isolated in bilateral skin loops, were blocked by cooling. To feed, a meat-based liquid food was infused by tube into the gastric fundus. MMC phases I, II, III, and IV were observed in the fasted state. On feeding, the fed pattern appeared quickly in the proximal small bowel but was delayed distally. Vagal blockade abolished all gastric contractions and spiking activity as well as the small bowel fed pattern. During vagal blockade, the small bowel exhibited MMC-like migrating bursts of spikes in both the fasted and fed states. The migration and cycling of these bursts were not significantly different from the MMC, but the duodenal and jejunal phase II was absent or shortened. On termination of vagal blockade, normal fasting or fed activity reappeared but with a delay in the fed pattern distally. We conclude: the ileum is the least sensitive to vagal blockade; the fasting vagal influence is exerted primarily on phases I and II of the duodenal and jejunal MMC; the fed pattern throughout the entire small bowel is normally dependent upon vagal integrity; the phase III-like bursts of activity seen during vagal blockade likely represents the intrinsic small bowel MMC, which is vagally independent.

Abstract CT187: Comparative analysis of randomized glioblastoma Phase III trials since 2005

2019 ◽  
Author(s):  
Lazaros Lazaridis ◽  
Ann-Kathrin Stoppek ◽  
Teresa Schmidt ◽  
Martin Glas ◽  
Sied Kebir
Keyword(s):  
Comparative Analysis ◽  
Phase Iii ◽  
Phase Iii Trials

Comparative analysis of durable responders on immune checkpoint inhibitors (ICI) versus other systemic therapies: A meta-analysis of phase III trials.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 3070-3070 ◽  
Author(s):  
Elvire Pons-Tostivint ◽  
Aurélien Latouche ◽  
Pauline Vaflard ◽  
Francesco Ricci ◽  
Delphine Loirat ◽  
...  
Keyword(s):  
Comparative Analysis ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Meta Analysis ◽  
Phase Iii ◽  
Phase Iii Trials ◽  
Systemic Therapies

scholarly journals M2016 Comparison of Small Bowel Postprandial Response in Healthy, Gastroparetic and Constipated Subjects as Measured by Wireless Motility Capsule (WMC)

2010 ◽  
Vol 138 (5) ◽  
pp. S-459 ◽  
Author(s):  
Margarita Brun ◽  
Whitney Michalek ◽  
Richard McCallum ◽  
Kenneth L. Koch ◽  
Michael D. Sitrin ◽  
...  
Keyword(s):  
Small Bowel ◽  
Wireless Motility Capsule ◽  
Postprandial Response

scholarly journals The latest first-line treatment options for ovarian cancer: focus on maintenance therapy

2020 ◽  
pp. 62-68
Author(s):  
A. A. Rumyantsev
Keyword(s):  
Ovarian Cancer ◽  
Comparative Analysis ◽  
Disease Progression ◽  
Treatment Options ◽  
Advanced Ovarian Cancer ◽  
Parp Inhibitors ◽  
Phase Iii ◽  
Published Data ◽  
Outpatient Basis ◽  
First Line

Ovarian cancer is one of the leading causes of death from gynecologic cancers in Russia: in 2018, 7616 women died from this disease and the proportion of patients who is under observation for 5 years or more was only 3.4%, which probably indicates very low 5-year survival. At the same time, there was is a tremendous paradigm shift in the treatment of BRCA-associated ovarian cancer. A number of large phase III trials have been published on the use of PARP inhibitors in this subtype of the disease. Their results demonstrated a marked reduction in the risk of disease progression or death with PARP inhibitors after first-line therapy for advanced ovarian cancer. Here we present a comparative analysis of the efficacy of various PARP inhibitors in BRCA-associated ovarian cancer. The relative risk reduction in disease progression or death for olaparib, niraparib and veliparib was 70%, 60% and 56%, respectively and advantage of using these drugs noted in all patient subgroups. Comparative analysis of the safety of various PARP inhibitors was carried out as well, the risks of developing various toxicity were assessed. Based on a comparison of published data on their safety profile, it was concluded that olaparib is the safest drug of this class, especially in the context of therapy on an outpatient basis. Possible ways to optimize the use of PARP inhibitors in disseminated ovarian cancer have been analyzed.

Sign in / Sign up

Export Citation Format

Share Document